The content on this site is intended for healthcare professionals only
Dr Haneen Shalabi speaks to ecancer in an online interview for the virtual AACR 2020 meeting.
She discusses the results of the phase 1 dose-escalation study evaluating the safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL.
Dr Shalabi goes through the background to the study and talks us through the methodology used.
She reports that the CAR T cells were well tolerated at all dose levels with a reversible side effect profile and patients did respond.
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
